연구용
제품 번호S1848
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| U87 | Cell viability assay | 0, 10, 20, 30, 40, and 50 µM/L | 24 hours | At concentrations higher than 20 µM/L, cell viabilities steeply declined | 31062527 | |
| HEL cells | Cell viability assay | 0-30 µmol/L | 24/48 hours | The viability of the HEL cells exposed to curcumin was significantly lower compared to control cells even at low concentrations. | 31033209 | |
| Raw246.7 | Cell viability assay | 1, 5, 10, 50, 100, 200, and 500 g/mL | 31007701 | |||
| RT112 | Cell viability assay | 0.1 or 0.4 μg/ml | 24, 48, and 72 h | Curcumin alone, added at a concentration from 0.1 to 0.4 μg/ml, did not alter cell growth of RT112 cells, slightly reduced UMUC3 cell growth at 0.4 μg/ml, and only moderately suppressed growth of TCCSUP at 0.2 and 0.4 μg/ml, each compared to respective controls | 30984278 | |
| UMUC3 | Cell viability assay | 0.1 or 0.4 μg/ml | 24, 48, and 73 h | Curcumin alone, added at a concentration from 0.1 to 0.4 μg/ml, did not alter cell growth of RT112 cells, slightly reduced UMUC3 cell growth at 0.4 μg/ml, and only moderately suppressed growth of TCCSUP at 0.2 and 0.5 μg/ml, each compared to respective controls | 30984278 | |
| TCCSUP | Cell viability assay | 0.1 or 0.4 μg/ml | 24, 48, and 74 h | Curcumin alone, added at a concentration from 0.1 to 0.4 μg/ml, did not alter cell growth of RT112 cells, slightly reduced UMUC3 cell growth at 0.4 μg/ml, and only moderately suppressed growth of TCCSUP at 0.2 and 0.6 μg/ml, each compared to respective controls | 30984278 | |
| KBM5 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human KBM5 cells after 72 hrs by MTT assay, IC50 = 3.84 μM. | 24280069 | ||
| Jurkat | Antiproliferative assay | 72 hrs | Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay, IC50 = 4.29 μM. | 24280069 | ||
| U266 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human U266 cells after 72 hrs by MTT assay, IC50 = 7.57 μM. | 24280069 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 17.3 μM. | 24280069 | ||
| MCF7 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay, IC50 = 32.2 μM. | 26174555 | ||
| SKOV3 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human SKOV3 cells after 24 hrs by MTT assay, IC50 = 43.63 μM. | 26174555 | ||
| CT26 | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 7.7 μM. | 26318057 | ||
| SW620 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 12.52 μM. | 26318057 | ||
| SGC7901 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SGC7901 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 24.41 μM. | 26318057 | ||
| GES-1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human GES-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 27.89 μM. | 26318057 | ||
| MGC803 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MGC803 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 31.39 μM. | 26318057 | ||
| Caco2 | Antiproliferative assay | Antiproliferative activity against human Caco2 cells, IC50 = 10.3 μM. | 26539626 | |||
| U2OS | Cytotoxicity assay | 48 hrs | Cytotoxicity against human U2OS cells expressing wild-type p53 after 48 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 22.8 μM. | 26606246 | ||
| Saos2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human Saos2 cells expressing p53 mutant after 48 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 28.1 μM. | 26606246 | ||
| U2OS | Cytotoxicity assay | 24 hrs | Cytotoxicity against human U2OS cells expressing wild-type p53 after 24 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 34.4 μM. | 26606246 | ||
| Saos2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human Saos2 cells expressing p53 mutant after 24 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 48.6 μM. | 26606246 | ||
| T98G | Antiproliferative assay | 24 hrs | Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay, IC50 = 10 μM. | 26631318 | ||
| T98G | Antiproliferative assay | 72 hrs | Antiproliferative activity against human T98G cells assessed as cell viability after 72 hrs by MTT assay, IC50 = 25 μM. | 26631318 | ||
| T67 | Neuroprotective assay | Neuroprotective effect in human T67 cells assessed as increase in NQO1 activity using DCIP as substrate | 26696252 | |||
| SH-SY5Y | Antiproliferative assay | 48 hrs | Antiproliferative activity against human SH-SY5Y cells assessed as cell viability after 48 hrs, IC50 = 16.1 μM. | 26705144 | ||
| HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs, IC50 = 21.8 μM. | 26705144 | ||
| HeLa | Cell cycle assay | 16 hrs | Cell cycle arrest in human HeLa cells assessed as accumulation at G1 phase at IC50 to 2 times IC50 after 16 hrs by FACS analysis | 26705144 | ||
| HuH7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HuH7 cells after 48 hrs by MTT assay, IC50 = 48 μM. | 26783179 | ||
| HeLa | Antiproliferative assay | 3 days | Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 12.11 μM. | 26827161 | ||
| LNCAP | Antiproliferative assay | 3 days | Antiproliferative activity against human LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 13.61 μM. | 26827161 | ||
| PC3 | Antiproliferative assay | 3 days | Antiproliferative activity against human PC3 cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 25.43 μM. | 26827161 | ||
| DU145 | Antiproliferative assay | 3 days | Antiproliferative activity against human DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 26.23 μM. | 26827161 | ||
| RAW264.7 | Antiinflammatory assay | 24 hrs | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay, IC50 = 19.1 μM. | 26841168 | ||
| BV2 | Function assay | 24 hrs | Inhibition of LPS-induced NO production in mouse BV2 cells assessed as reduction in nitrite level pretreated for 24 hrs before LPS treatment for additional 24 hrs by Griess reaction method, IC50 = 0.52 μM. | 26859776 | ||
| HepG2 | Cytotoxicity assay | Cytotoxicity activity against human HepG2 cells by MTT assay, IC50 = 4.43 μM. | 26873414 | |||
| A549 | Cytotoxicity assay | Cytotoxicity against human A549 cells by MTT assay, IC50 = 23.54 μM. | 26873414 | |||
| MCF7 | Cytotoxicity assay | Cytotoxicity against human MCF7 cells by MTT assay, IC50 = 46.25 μM. | 26873414 | |||
| SKOV3 | Cytotoxicity assay | Cytotoxicity against human SKOV3 cells by MTT assay, IC50 = 49.85 μM. | 26873414 | |||
| A549/CDDP | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay, IC50 = 32.39 μM. | 26891099 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 38.12 μM. | 26891099 | ||
| A549/CDDP | Function assay | Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry, IC50 = 39.42 μM. | 26891099 | |||
| A549 | Function assay | Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry, IC50 = 40.56 μM. | 26891099 | |||
| A549 | Apoptosis assay | 2.1 to 4.2 uM | 24 hrs | Induction of apoptosis in human A549 cells at 2.1 to 4.2 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry | 26891099 | |
| A549/CDDP | Apoptosis assay | 0.6 to 1.2 uM | 24 hrs | Induction of apoptosis in human A549/CDDP cells at 0.6 to 1.2 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry | 26891099 | |
| bone marrow | Function assay | 48 hrs | Inhibition of RANKL-induced osteoclast differentiation in ICR mouse bone marrow cells after 48 hrs by TRAP assay, IC50 = 7.5 μM. | 26923696 | ||
| U937 | Function assay | 17 to 20 hrs | Inhibition of LPS/IFN-gamma-induced PGE2 production in PMA-treated human U937 cells after 17 to 20 hrs by enzyme immunoassay, IC50 = 1.88 μM. | 27040659 | ||
| RAW264.7 | Function assay | 17 to 20 hrs | Inhibition of LPS/IFN-gamma-induced PGE2 production in mouse RAW264.7 cells after 17 to 20 hrs by enzyme immunoassay, IC50 = 15.95 μM. | 27040659 | ||
| BV2 | Antiinflammatory assay | 24 hrs | Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay, IC50 = 4.77 μM. | 27228227 | ||
| SH-SY5Y | Neuroprotective assay | 24 hrs | Neuroprotective activity in human SH-SY5Y cells assessed as reduction in 6-OHDA-induced cell death measured after 24 hrs by MTT assay, EC50 = 6.2 μM. | 27420919 | ||
| PC3 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay, IC50 = 39 μM. | 27496212 | ||
| DU145 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay, IC50 = 41 μM. | 27496212 | ||
| 4T1 | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay, IC50 = 49.4 μM. | 27496212 | ||
| T47D | Cytotoxicity assay | 24 hrs | Cytotoxicity against human T47D cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 30 μM. | 27517806 | ||
| CHOK1 | Growth inhibition assay | 72 hrs | Growth inhibition of CHOK1 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay, IC50 = 7.5 μM. | 27521589 | ||
| LNCAP | Antiproliferative assay | 3 days | Antiproliferative activity against human LNCAP cells after 3 days by WST or trypan blue assay, IC50 = 13.61 μM. | 27543391 | ||
| PC3 | Antiproliferative assay | 3 days | Antiproliferative activity against human PC3 cells after 3 days by WST or trypan blue assay, IC50 = 25.43 μM. | 27543391 | ||
| DU145 | Antiproliferative assay | 3 days | Antiproliferative activity against human DU145 cells after 3 days by WST or trypan blue assay, IC50 = 26.23 μM. | 27543391 | ||
| BV2 | Function assay | 1 hr | Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 1 hr before LPS stimulation measured after 24 hrs by Griess assay, IC50 = 1.42 μM. | 27592135 | ||
| BV2 | Function assay | 1 hr | Inhibition of Src in mouse BV2 cells assessed as suppression of LPS-induced NO release preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess assay, IC50 = 2.2 μM. | 27617803 | ||
| A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells after 48 hrs by MTT assay, IC50 = 15.06 μM. | 27816267 | ||
| MDA-MB-231 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 24.54 μM. | 27816267 | ||
| DU145 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay, IC50 = 44.71 μM. | 27816267 | ||
| EAhy926 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 24.6 μM. | 27843113 | ||
| Caco2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 38.3 μM. | 27843113 | ||
| CHOK1 | Cytotoxicity assay | 48 hrs | Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 42 μM. | 27843113 | ||
| SH-SY5Y | Function assay | 1 to 5 uM | 24 hrs | Antioxidant activity against t-BHP-induced oxidative stress in human SH-SY5Y cells assessed as inhibition of ROS production at 1 to 5 uM after 24 hrs by DCFH-DA probe based flow cytometric analysis | 27856236 | |
| NCI-H1650 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H1650 cells measured after 72 hrs by MTT assay, IC50 = 20.7 μM. | 27886548 | ||
| LLC | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse LLC cells measured after 72 hrs by MTT assay, IC50 = 24.7 μM. | 27886548 | ||
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay, IC50 = 27.8 μM. | 27886548 | ||
| K562 | Function assay | 48 hrs | Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay, GI50 = 19.67 μM. | 27908756 | ||
| K562 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay, GI50 = 21.67 μM. | 27908756 | ||
| H460 | Function assay | 48 hrs | Inhibition of P-gp in drug resistant human H460 cells assessed as reduction in cell viability measured after 48 hrs by sulforhodamine B assay, GI50 = 26 μM. | 27908756 | ||
| NCI-H460 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay, GI50 = 27.3 μM. | 27908756 | ||
| K562 | Function assay | 20 to 30 uM | 48 hrs | Down regulation of p-gp expression in doxorubicin resistant human K562 cells at 20 to 30 uM measured after 48 hrs by Western blot method | 27908756 | |
| K562 | Cell cycle assay | 20 uM | 48 hrs | Cell cycle arrest in doxorubicin resistant human K562 cells assessed as decrease in G0/G1 phase at 20 uM measured after 48 hrs by propidium iodide staining based flow cytometry | 27908756 | |
| K562 | Cell cycle assay | 20 uM | 48 hrs | Cell cycle arrest in doxorubicin resistant human K562 cells assessed as increase in G2/M phase at 20 uM measured after 48 hrs by propidium iodide staining based flow cytometry | 27908756 | |
| K562 | Function assay | 20 to 40 uM | 48 hrs | Up regulation of p53 expression in doxorubicin resistant human K562 cells at 20 to 40 uM measured after 48 hrs by Western blot method | 27908756 | |
| K562 | Cell cycle assay | 20 uM | 48 hrs | Cell cycle arrest in doxorubicin resistant human K562 cells assessed as decrease in S phase at 20 uM measured after 48 hrs by propidium iodide staining based flow cytometry | 27908756 | |
| K562 | Cell cycle assay | 30 to 40 uM | 48 hrs | Cell cycle arrest in doxorubicin resistant human K562 cells assessed as accumulation at G0/G1 phase at 30 to 40 uM measured after 48 hrs by propidium iodide staining based flow cytometry | 27908756 | |
| K562 | Cell cycle assay | 30 to 40 uM | 48 hrs | Cell cycle arrest in doxorubicin resistant human K562 cells assessed as decrease in G2/M phase at 30 to 40 uM measured after 48 hrs by propidium iodide staining based flow cytometry | 27908756 | |
| K562 | Function assay | 20 to 40 uM | 48 hrs | Down regulation of cyclin B1 expression in doxorubicin resistant human K562 cells at 20 to 40 uM measured after 48 hrs by Western blot method | 27908756 | |
| K562 | Apoptosis assay | 20 to 40 uM | 48 hrs | Induction of apoptosis in doxorubicin resistant human K562 cells decrease in pro-caspase 3 level at 20 to 40 uM measured after 48 hrs by Western blot method | 27908756 | |
| K562 | Apoptosis assay | 20 to 40 uM | 48 hrs | Induction of apoptosis in doxorubicin resistant human K562 cells assessed as increase in PARP-1 cleavage at 20 to 40 uM measured after 48 hrs by Western blot method | 27908756 | |
| Raji | Function assay | 48 hrs | Inhibition of TPA-induced EBV-early antigen activation in human Raji cells after 48 hrs by indirect immunofluorescence method, IC50 = 12.1 μM. | 27933896 | ||
| BV2 | Function assay | 24 hrs | Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 24 hrs followed by LPS-stimulation after 24 hrs by Griess assay, IC50 = 2.36 μM. | 28032759 | ||
| PC3 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay, IC50 = 12.22 μM. | 28038323 | ||
| MDA-MB-231 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 15.81 μM. | 28038323 | ||
| BT549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay, IC50 = 24.93 μM. | 28038323 | ||
| HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay, IC50 = 25.41 μM. | 28038323 | ||
| DU145 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay, IC50 = 28.41 μM. | 28038323 | ||
| BV2 | Function assay | 30 mins | Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 30 mins followed by LPS-stimulation after 24 hrs by Griess assay, IC50 = 4.5 μM. | 28055210 | ||
| THP1 | Function assay | 1 hr | Inhibition of LPS-induced tissue factor procoagulant activity in human THP1 cells preincubated for 1 hr followed by LPS addition measured after 5 hrs using factor 10a chromogenic substrate in presence of prothrombin complex, IC50 = 0.01316 μM. | 28109788 | ||
| RAW264.7 | Antiinflammatory assay | 20 uM | Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production at 20 uM by ELISA | 28284806 | ||
| RAW264.7 | Antiinflammatory assay | 20 uM | Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 20 uM by ELISA | 28284806 | ||
| PC12 | Neuroprotective assay | 0.1 to 10 uM | 24 hrs | Neuroprotective activity against H202-induced toxicity in rat PC12 cells assessed as increase in cell viability at 0.1 to 10 uM after 24 hrs by MTT assay | 28302511 | |
| PC12 | Neuroprotective assay | 0.1 to 10 uM | 24 hrs | Neuroprotective activity against Abeta42-induced toxicity in rat PC12 cells assessed as increase in cell viability at 0.1 to 10 uM after 24 hrs by MTT assay | 28302511 | |
| HCT116 | Antiproliferative assay | Antiproliferative activity against human HCT116 cells up to 72 hrs by MTT assay, IC50 = 13.77 μM. | 28319780 | |||
| MDA-MB-231 | Antiproliferative assay | Antiproliferative activity against human MDA-MB-231 cells up to 72 hrs by MTT assay, IC50 = 16.23 μM. | 28319780 | |||
| PC3 | Antiproliferative assay | Antiproliferative activity against human PC3 cells up to 72 hrs by MTT assay, IC50 = 18.8 μM. | 28319780 | |||
| BT474 | Antiproliferative assay | 24 hrs | Antiproliferative activity against HER2 positive human BT474 cells after 24 hrs by MTT assay, IC50 = 30.14 μM. | 28319780 | ||
| MDA-MB-453 | Antiproliferative assay | 24 hrs | Antiproliferative activity against HER2 positive human MDA-MB-453 cells after 24 hrs by MTT assay, IC50 = 32.4 μM. | 28319780 | ||
| MDA-MB-157 | Antiproliferative assay | 24 hrs | Antiproliferative activity against human MDA-MB-157 cells after 24 hrs by MTT assay, IC50 = 40.38 μM. | 28319780 | ||
| SKBR3 | Antiproliferative assay | 24 hrs | Antiproliferative activity against HER2 positive human SKBR3 cells after 24 hrs by MTT assay, IC50 = 42.83 μM. | 28319780 | ||
| MCF7 | Antiproliferative assay | 24 hrs | Antiproliferative activity against ER/PR positive human MCF7 cells after 24 hrs by MTT assay, IC50 = 42.89 μM. | 28319780 | ||
| MDA-MB-468 | Antiproliferative assay | 24 hrs | Antiproliferative activity against human MDA-MB-468 cells after 24 hrs by MTT assay, IC50 = 42.89 μM. | 28319780 | ||
| T47D | Antiproliferative assay | 24 hrs | Antiproliferative activity against ER/PR positive human T47D cells after 24 hrs by MTT assay, IC50 = 47.91 μM. | 28319780 | ||
| cells at | Growth inhibition assay | 30 uM | 48 hrs | Growth inhibition of human Hep3B cells at 30 uM after 48 hrs by MTT assay | 28342400 | |
| PWR-1E | Antiproliferative assay | 3 days | Antiproliferative activity against human PWR-1E cells after 3 days by WST-1 assay, IC50 = 8.14 μM. | 28388523 | ||
| LNCAP | Antiproliferative assay | 3 days | Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay, IC50 = 13.61 μM. | 28388523 | ||
| PC3 | Antiproliferative assay | 3 days | Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay, IC50 = 25.43 μM. | 28388523 | ||
| DU145 | Antiproliferative assay | 3 days | Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay, IC50 = 26.23 μM. | 28388523 | ||
| HepG2 | Function assay | 5 uM | 24 hrs | Activation of Nrf2 in human HepG2 cells assessed as cytoprotection against t-BHP-induced oxidative cell death at 5 uM incubated for 24 hrs followed by compound removal with subsequent incubation with 900 uM of t-BHP for 6 hrs by MTT assay | 28399452 | |
| BV2 | Antineuroinflammatory assay | 15 mins | Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 15 mins followed by LPS-stimulation measured after 24 hrs by colorimetric method, IC50 = 6 μM. | 28514148 | ||
| L428 | Function assay | 2 hrs | Inhibition of NF-kappaB (unknown origin) expressed in human L428 cells after 2 hrs by luciferase reporter gene assay | 28526369 | ||
| PWR-1E | Antiproliferative assay | 3 days | Antiproliferative activity against human PWR-1E cells expressing androgen receptor and PSA assessed as decrease in cell viability after 3 days by WST assay, IC50 = 8.85 μM. | 28601720 | ||
| LNCAP | Antiproliferative assay | 3 days | Antiproliferative activity against human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 13.61 μM. | 28601720 | ||
| PC3 | Antiproliferative assay | 3 days | Antiproliferative activity against human PC3 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 25.43 μM. | 28601720 | ||
| DU145 | Antiproliferative assay | 3 days | Antiproliferative activity against human DU145 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 26.23 μM. | 28601720 | ||
| MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 12 μM. | 28654265 | ||
| HT-29 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 14 μM. | 28654265 | ||
| NCI-H460 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 15 μM. | 28654265 | ||
| LN229 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 15 μM. | 28654265 | ||
| U87 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 16 μM. | 28654265 | ||
| COLO201 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 18 μM. | 28654265 | ||
| A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 18 μM. | 28654265 | ||
| T47D | Cytotoxicity assay | 48 hrs | Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 19 μM. | 28654265 | ||
| MML1 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MML1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 19 μM. | 28654265 | ||
| BxPC3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 29 μM. | 28654265 | ||
| SK-MEL-2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 36 μM. | 28654265 | ||
| HCT116 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay, GI50 = 3.5 μM. | 28716495 | ||
| HCT116 | Function assay | 48 hrs | Induction of mitochondrial membrane potential loss in human HCT116 cells at antiproliferative GI50 after 48 hrs by JC-1 staining based fluorescence assay | 28716495 | ||
| HCT116 | Function assay | 60 mins | Induction of mitochondrial superoxide generation in human HCT116 cells at antiproliferative GI50 after 60 mins by mitoSOX red-probe based fluorescence assay | 28716495 | ||
| HCT116 | Function assay | 60 mins | Induction of reactive oxygen species generation in human HCT116 cells at antiproliferative GI50 after 60 mins by DCFH-DA probe based assay | 28716495 | ||
| HCT116 | Function assay | 500 uM | 48 hrs | Induction of glutathione oxidation in human HCT116 cells assessed as increase in GSSG/GSH ratio at 500 uM in presence of NADPH after 48 hrs by Ellman's method | 28716495 | |
| MCF7 | Function assay | 48 hrs | Modulation activity at ER in human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 48 μM. | 28797797 | ||
| A549 | Growth inhibition assay | Growth inhibition of human A549 cells, IC50 = 23 μM. | 28814374 | |||
| BGC823 | Growth inhibition assay | 20 uM | 72 hrs | Growth inhibition of human BGC823 cells at 20 uM after 72 hrs by MTT assay | 28881286 | |
| SGC7901 | Growth inhibition assay | 20 uM | 72 hrs | Growth inhibition of human SGC7901 cells at 20 uM after 72 hrs by MTT assay | 28881286 | |
| MFC | Growth inhibition assay | 20 uM | 72 hrs | Growth inhibition of MFC cells at 20 uM after 72 hrs by MTT assay | 28881286 | |
| BV2 | Antiinflammatory assay | 24 hrs | Antiinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay, IC50 = 4 μM. | 29035525 | ||
| NCI-H460 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 17.14 μM. | 29174816 | ||
| PC3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 18.71 μM. | 29174816 | ||
| DU145 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 33.12 μM. | 29174816 | ||
| HepG2 | Function assay | 5 hrs | Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay, EC50 = 21 μM. | 29223100 | ||
| BGC823 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human BGC823 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 19.5 μM. | 29288946 | ||
| NCI-H460 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 20.3 μM. | 29288946 | ||
| SGC7901 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SGC7901 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 26.2 μM. | 29288946 | ||
| NCI-H460 | Growth inhibition assay | 5 to 10 uM | 24 to 72 hrs | Growth inhibition of human NCI-H460 cells assessed as reduction in cell viability at 5 to 10 uM incubated for 24 to 72 hrs by MTT assay | 29288946 | |
| NCI-H460 | Growth inhibition assay | 20 uM | 18 hrs | Anti-growth activity against human NCI-H460 cells assessed as reduction in colony formation at 20 uM after 18 hrs by crystal violet-based colony forming assay | 29288946 | |
| NCI-H460 | Antimigratory assay | 20 uM | 48 hrs | Anti-migratory activity against human NCI-H460 cells at 20 uM incubated for 48 hrs by wound healing assay | 29288946 | |
| NCI-H460 | Apoptosis assay | 15 mg/kg | 15 days | Induction of apoptosis in tumor of human NCI-H460 cells xenografted in BALB/C nu nude mouse assessed as downregulation of bcl2 expression at 15 mg/kg, ip administered everyday for 15 days by Western blot analysis | 29288946 | |
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 13.78 μM. | 29421568 | ||
| THP1 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 22.54 μM. | 29421568 | ||
| K562 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 23.12 μM. | 29421568 | ||
| LO2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 25.67 μM. | 29421568 | ||
| HeLa | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 31.89 μM. | 29421568 | ||
| NCI-H460 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 17.11 μM. | 29429834 | ||
| PC3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 18.65 μM. | 29429834 | ||
| DU145 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 33.15 μM. | 29429834 | ||
| MCF7 | Cytotoxicity assay | 4 hrs | Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay, IC50 = 22.1 μM. | 29605808 | ||
| WRL68 | Cytotoxicity assay | 4 hrs | Cytotoxicity against human WRL68 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay, IC50 = 27.8 μM. | 29605808 | ||
| A549 | Cytotoxicity assay | 4 hrs | Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay, IC50 = 43.9 μM. | 29605808 | ||
| NCI-H1975 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 1.4 μM. | 29655083 | ||
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 6.8 μM. | 29655083 | ||
| HL7702 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 7.2 μM. | 29655083 | ||
| H460 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 8.5 μM. | 29655083 | ||
| NCI-H1650 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 20.5 μM. | 29655083 | ||
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 10 μM. | 29798827 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay, IC50 = 10.91 μM. | 29886021 | ||
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 16.01 μM. | 29909338 | ||
| SMMC7721 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 19.47 μM. | 29909338 | ||
| QGY7703 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 21.44 μM. | 29909338 | ||
| HHL5 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HHL5 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 22.27 μM. | 29909338 | ||
| LO2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 23.87 μM. | 29909338 | ||
| Vero | Cytotoxicity assay | Cytotoxicity against African green monkey Vero cells assessed as growth inhibition, CC50 = 36.8 μM. | 29920454 | |||
| HT22 | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse HT22 cells assessed as reduction in cell viability after 24 hrs by MTT assay, MNTD = 1 μM. | 30031653 | ||
| HT22 | Cytoprotection assay | 1 uM | 24 hrs | Cytoprotection against glutamate-induced apoptosis in mouse HT22 cells assessed as decrease in Bax/Bcl2 ratio at 1 uM after 24 hrs by RT-PCR method | 30031653 | |
| HT22 | Cytoprotection assay | 1 uM | 24 hrs | Cytoprotection against glutamate-induced oxidative stress in mouse HT22 cells assessed as decrease in iNOS mRNA level at 1 uM after 24 hrs by RT-PCR method | 30031653 | |
| HT22 | Cytoprotection assay | 1 uM | 24 hrs | Cytoprotection against glutamate-induced excitotoxicity in mouse HT22 cells assessed as increase in cell viability at 1 uM after 24 hrs by optical microscopic assay | 30031653 | |
| HT22 | Cytoprotection assay | 1 uM | 24 hrs | Cytoprotection against glutamate-induced excitotoxicity in mouse HT22 cells assessed as decrease in glutamate-induced cell cycle arrest at sub-G1 phase at 1 uM after 24 hrs by propidium iodide staining based flow cytometry | 30031653 | |
| HT22 | Cytoprotection assay | 1 uM | 24 hrs | Cytoprotection against glutamate-induced excitotoxicity in mouse HT22 cells assessed as increase in cell proliferation at 1 uM after 24 hrs by MTT assay | 30031653 | |
| LNCAP | Antiproliferative assay | Antiproliferative activity against androgen-sensitive human LNCAP cells, IC50 = 2 μM. | 30121214 | |||
| DU145 | Antiproliferative assay | Antiproliferative activity against androgen-insensitive human DU145 cells, IC50 = 2 μM. | 30121214 | |||
| PC3 | Antiproliferative assay | Antiproliferative activity against androgen-insensitive human PC3 cells, IC50 = 2 μM. | 30121214 | |||
| LNCAP | Antiproliferative assay | 3 days | Antiproliferative activity against androgen-sensitive human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 13.61 μM. | 30121214 | ||
| PC3 | Antiproliferative assay | 3 days | Antiproliferative activity against androgen-insensitive human PC3 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 25.43 μM. | 30121214 | ||
| DU145 | Antiproliferative assay | 3 days | Antiproliferative activity against androgen-insensitive human DU145 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 26.23 μM. | 30121214 | ||
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 9.8 μM. | 30138803 | ||
| EJ28 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human EJ28 cells after 72 hrs by MTT assay, IC50 = 10.5 μM. | 30138803 | ||
| HT1080 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay, IC50 = 13.1 μM. | 30138803 | ||
| SW620 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SW620 cells after 72 hrs by MTT assay, IC50 = 14 μM. | 30138803 | ||
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 17.9 μM. | 30138803 | ||
| SMMC7721 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 16.68 μM. | 30771605 | ||
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 17.37 μM. | 30771605 | ||
| LO2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 22.69 μM. | 30771605 | ||
| QGY7703 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 23.91 μM. | 30771605 | ||
| HHL5 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HHL5 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 24.19 μM. | 30771605 | ||
| HCT-116 | Function assay | 24 hrs | Inhibition of chymotrypsin-like activity of human 26S proteasome in human HCT-116 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometr, IC50 = 10 μM. | 30776692 | ||
| SW480 | Function assay | 24 hrs | Inhibition of chymotrypsin-like activity of human 26S proteasome in human SW480 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometric, IC50 = 10 μM. | 30776692 | ||
| RAW264.7 | Function assay | 10 uM | 0.5 hrs | Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced TNFalpha production at 10 uM pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA relative to control | 30780088 | |
| RAW264.7 | Function assay | 0.5 hrs | Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced TNFalpha production pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA | 30780088 | ||
| RAW264.7 | Function assay | 0.5 hrs | Inhibition of LPS-induced NFkappaB p65 nuclear translocation in ICR mouse RAW264.7 cells preincubated for 0.5 hrs followed by LPS challenge and measured after 40 mins by DAPI staining-based immunofluorescence microscopic analysis | 30780088 | ||
| RAW264.7 | Function assay | 10 uM | 0.5 hrs | Inhibition of LPS-induced p38 MAPK phosphorylation in ICR mouse RAW264.7 cells at 10 uM preincubated for 0.5 hrs followed by LPS challenge and measured after 30 mins by immunoblotting analysis | 30780088 | |
| RAW264.7 | Function assay | 10 uM | 0.5 hrs | Inhibition of LPS-induced ERK phosphorylation in ICR mouse RAW264.7 cells at 10 uM preincubated for 0.5 hrs followed by LPS challenge and measured after 30 mins by immunoblotting analysis | 30780088 | |
| RAW264.7 | Function assay | 10 uM | 0.5 hrs | Inhibition of NFkappaB/MAPK signaling in LPS-induced mouse RAW264.7 cells assessed as down regulation of IkappaB expression at 10 uM preincubated for 0.5 hrs followed by LPS-challenge and measured after 30 mins by immunoblotting analysis | 30780088 | |
| RAW264.7 | Function assay | 10 uM | 0.5 hrs | Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced IL6 production at 10 uM pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA relative to control | 30780088 | |
| RAW264.7 | Function assay | 0.5 hrs | Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced IL6 production pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA | 30780088 | ||
| RAW264.7 | Function assay | 4 hrs | Inhibition of RANKL-induced osteoclastogenesis in murine RAW264.7 cells assessed as formation of TRAP positive multinucleated osteoclasts pretreated for 4 hrs followed by RANKL addition measured after 72 hrs, IC50 = 3 μM. | 30794412 | ||
| BV2 | Antineuroinflammatory assay | 1 hr | Anti-neuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess reagent based assay, IC50 = 1.58 μM. | 31005056 | ||
| HeLa | Anticancer assay | Anticancer activity against human HeLa cells, IC50 = 4.33 μM. | 31129455 | |||
| HL60 | Cytotoxicity assay | Cytotoxicity against human HL60 cells, IC50 = 6.3 μM. | 31129455 | |||
| SKOV3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human SKOV3 Cells after 48 hrs by Cell Titer Blue assay, IC50 = 6.7 μM. | 31129455 | ||
| HSC4 | Cytotoxicity assay | Cytotoxicity against human HSC4 cells, IC50 = 7.1 μM. | 31129455 | |||
| U87MG | Cytotoxicity assay | 48 hrs | Cytotoxicity against human U87MG Cells 48 hrs by MTS assay, IC50 = 7.15 μM. | 31129455 | ||
| HSC2 | Cytotoxicity assay | Cytotoxicity against human HSC2 cells, IC50 = 7.8 μM. | 31129455 | |||
| LX2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human LX2 Cells after 48 hrs by MTT assay, IC50 = 9.14 μM. | 31129455 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 Cells after 48 hrs by MTT assay, IC50 = 9.28 μM. | 31129455 | ||
| HepG2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HepG2 Cells after 48 hrs by MTT assay, IC50 = 9.44 μM. | 31129455 | ||
| 3T3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against mouse 3T3 Cells after 48 hrs by MTT assay, IC50 = 9.51 μM. | 31129455 | ||
| AGS | Cytotoxicity assay | Cytotoxicity against human AGS Cells, IC50 = 9.77 μM. | 31129455 | |||
| HSC3 | Cytotoxicity assay | Cytotoxicity against human HSC3 cells, IC50 = 11 μM. | 31129455 | |||
| MDA-MB-231 | Anticancer assay | 72 hrs | Anticancer activity against human MDA-MB-231 cells after 72 hrs by MTT assay, IC50 = 11.45 μM. | 31129455 | ||
| SMMC7721 | Anticancer assay | 72 hrs | Anticancer activity against human SMMC7721 cells after 72 hrs by MTT assay, IC50 = 12.57 μM. | 31129455 | ||
| LX2 | Anticancer assay | 72 hrs | Anticancer activity against human LX2 cells after 72 hrs by MTT assay, IC50 = 13.97 μM. | 31129455 | ||
| HeLa | Cytotoxicity assay | Cytotoxicity against human HeLa Cells, IC50 = 14.03 μM. | 31129455 | |||
| SW480 | Cytotoxicity assay | 24 to 48 hrs | Cytotoxicity against human SW480 Cells after 24 to 48 hrs by MTT assay, IC50 = 15 μM. | 31129455 | ||
| U251MG | Cytotoxicity assay | 48 hrs | Cytotoxicity against human U251MG cells after 48 hrs by MTS assay, IC50 = 15.26 μM. | 31129455 | ||
| RWPE1 | Cytotoxicity assay | Cytotoxicity against human RWPE1 cells, IC50 = 15.62 μM. | 31129455 | |||
| MCF7 | Apoptosis assay | Induction of apoptosis in human MCF7 cells, IC50 = 17.1 μM. | 31129455 | |||
| BGC823 | Cytotoxicity assay | Cytotoxicity against human BGC823 cells, IC50 = 17.5 μM. | 31129455 | |||
| BxPC3 | Cytotoxicity assay | Cytotoxicity against human BxPC3 cells, IC50 = 18.25 μM. | 31129455 | |||
| HT-29 | Cytotoxicity assay | Cytotoxicity against human HT-29 Cells, IC50 = 18.74 μM. | 31129455 | |||
| H1299 | Cytotoxicity assay | Cytotoxicity against human H1299 cells, IC50 = 18.93 μM. | 31129455 | |||
| PC3 | Cytotoxicity assay | Cytotoxicity against human PC3 cells, IC50 = 19.98 μM. | 31129455 | |||
| EAhy926 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human EAhy926 Cells after 72 hrs by MTT assay, IC50 = 20 μM. | 31129455 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 Cells after 72 hrs by MTT assay, IC50 = 20.3 μM. | 31129455 | ||
| AGS | Cytotoxicity assay | Cytotoxicity against human AGS Cells by MTT assay, IC50 = 20.76 μM. | 31129455 | |||
| PC3 | Anticancer assay | Anticancer activity against human PC3 cells, IC50 = 20.9 μM. | 31129455 | |||
| MGC803 | Cytotoxicity assay | Cytotoxicity against human MGC803 cells, IC50 = 21.2 μM. | 31129455 | |||
| CHOK1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human CHOK1 Cells after 72 hrs by MTT assay, IC50 = 21.3 μM. | 31129455 | ||
| Hep2 | Cytotoxicity assay | Cytotoxicity against human Hep2 Cells, IC50 = 21.37 μM. | 31129455 | |||
| MCF7 | Cytotoxicity assay | Cytotoxicity against human MCF7 cells, IC50 = 22.5 μM. | 31129455 | |||
| SGC7901 | Cytotoxicity assay | Cytotoxicity against human SGC7901 cells, IC50 = 22.5 μM. | 31129455 | |||
| HT-29 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HT-29 Cells after 72 hrs by MTT assay, IC50 = 23.4 μM. | 31129455 | ||
| A549 | Cytotoxicity assay | Cytotoxicity against human A549 Cells by MTT assay, IC50 = 25.33 μM. | 31129455 | |||
| MDA-MB-231 | Cytotoxicity assay | Cytotoxicity against human MDA-MB-231 cells, IC50 = 26.5 μM. | 31129455 | |||
| A549 | Cytotoxicity assay | 24 to 48 hrs | Cytotoxicity against human A549 Cells after 24 to 48 hrs by MTT assay, IC50 = 28 μM. | 31129455 | ||
| Caco2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human Caco2 Cells after 72 hrs by MTT assay, IC50 = 28 μM. | 31129455 | ||
| GES-1 | Cytotoxicity assay | Cytotoxicity against human GES-1 cells, IC50 = 29.1 μM. | 31129455 | |||
| DU145 | Anticancer assay | Anticancer activity against human DU145 cells, IC50 = 31.7 μM. | 31129455 | |||
| MDCK2 | Cytotoxicity assay | 15 mins | Cytotoxicity against mitoxantrone resistant human MDCK2 cells expressing BCRP after 15 mins by fluorescence assay, IC50 = 32 μM. | 31129455 | ||
| HL-7702 | Cytotoxicity assay | Cytotoxicity against human HL-7702 cells, IC50 = 32.33 μM. | 31129455 | |||
| K562 | Cytotoxicity assay | 24 to 48 hrs | Cytotoxicity against human K562 Cells after 24 to 48 hrs by MTT assay, IC50 = 36 μM. | 31129455 | ||
| HepG2 | Cytotoxicity assay | Cytotoxicity against human HepG2 Cells, IC50 = 36.77 μM. | 31129455 | |||
| GBM1 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human GBM1 Cells 48 hrs by MTS assay, IC50 = 39.65 μM. | 31129455 | ||
| PC12 | Cytotoxicity assay | 24 hrs | Cytotoxicity against rat PC12 cells measured after 24 hrs by WST8/PMS assay, CC50 = 42 μM. | 31262559 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 10.5 μM. | 31326241 | ||
| HeLa | Cytotoxicity assay | Cytotoxicity against human HeLa cells, IC50 = 8.2 μM. | 31336310 | |||
| B16 | Cytotoxicity assay | Cytotoxicity against human B16 cells by MTT assay, IC50 = 8.5 μM. | 31336310 | |||
| HT1080 | Function assay | Decrease in UPA expression in human HT1080 cells, IC50 = 10 μM. | 31336310 | |||
| Hep3B | Cytotoxicity assay | Cytotoxicity against human Hep3B cells, IC50 = 10 μM. | 31336310 | |||
| BT474 | Cytotoxicity assay | Cytotoxicity against human BT474 cells, IC50 = 11 μM. | 31336310 | |||
| T47D | Cytotoxicity assay | Cytotoxicity against human T47D cells, IC50 = 11 μM. | 31336310 | |||
| HaCaT | Cytotoxicity assay | Cytotoxicity against human HaCaT cells, IC50 = 13 μM. | 31336310 | |||
| KM12 | Cytotoxicity assay | 4 hrs | Cytotoxicity against human KM12 cells after 4 hrs by MTT assay, IC50 = 16 μM. | 31336310 | ||
| HPL1D | Cytotoxicity assay | Cytotoxicity against human HPL1D cells, IC50 = 16 μM. | 31336310 | |||
| SW480 | Cytotoxicity assay | 4 hrs | Cytotoxicity against human SW480 cells after 4 hrs by MTT assay, IC50 = 17.94 μM. | 31336310 | ||
| MCF7 | Cytotoxicity assay | Cytotoxicity against human MCF7 cells, IC50 = 19.9 μM. | 31336310 | |||
| HT-29 | Cytotoxicity assay | 4 hrs | Cytotoxicity against human HT-29 cells after 4 hrs by MTT assay, IC50 = 20.73 μM. | 31336310 | ||
| WiDr | Cytotoxicity assay | 4 hrs | Cytotoxicity against human WiDr cells after 4 hrs by MTT assay, IC50 = 26.82 μM. | 31336310 | ||
| SW116 | Cytotoxicity assay | 4 hrs | Cytotoxicity against human SW116 cells after 4 hrs by MTT assay, IC50 = 27.46 μM. | 31336310 | ||
| Colon 26 | Cytotoxicity assay | 4 hrs | Cytotoxicity against mouse Colon 26 cells after 4 hrs by MTT assay, IC50 = 30.34 μM. | 31336310 | ||
| 22Rv1 | Function assay | Inhibition of NFkappaB p65 nuclear translocation in human 22Rv1 cells at GI50 by DAPI staining based immunofluorescence assay | 31767266 | |||
| PC3 | Antiproliferative assay | 48 hrs | Antiproliferative activity human PC3 cells assessed as reduction in Ki67 protein level at GI50 incubated for 48 hrs by DAPI staining based immunofluorescence assay | 31767266 | ||
| 22Rv1 | Antiproliferative assay | 48 hrs | Antiproliferative activity human 22Rv1 cells assessed as reduction in Ki67 protein level at GI50 incubated for 48 hrs by DAPI staining based immunofluorescence assay | 31767266 | ||
| PC3 | Function assay | Inhibition of NFkappaB p65 nuclear translocation in human PC3 cells at GI50 by DAPI staining based immunofluorescence assay | 31767266 | |||
| PC3 | Function assay | Inhibition of NFkappaB p65 transcriptional activity in human PC3 cells at GI50 by sandwich ELISA | 31767266 | |||
| 22Rv1 | Function assay | Inhibition of NFkappaB p65 transcriptional activity in human 22Rv1 cells at GI50 by sandwich ELISA | 31767266 | |||
| Sf21 | Function assay | 10 mins | Inhibition of recombinant human full-length His6-tagged p300 expressed in baculovirus infected Sf21 insect cells using [3H]acetylCoA as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by liquid scintillation co, IC50 = 25 μM. | 31910017 | ||
| COS7 | Function assay | 10 mins | Inhibition of rabbit SERCA1b expressed in COS7 cells microsomal membranes preincubated for 10 mins followed by addition of ATP and measured after 40 mins by ELISA method, Ki = 5.8 μM. | 32030976 | ||
| COS7 | Function assay | 10 mins | Inhibition of human SERCA3a expressed in COS7 cells microsomal membranes preincubated for 10 mins followed by addition of ATP and measured after 40 mins by ELISA method, Ki = 8.6 μM. | 32030976 | ||
| A549 | Function assay | 15 mins | Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis, IC50 = 0.2 μM. | ChEMBL | ||
| RAW264.7 | Function assay | 20 hrs | Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 20 hrs by griess assay, IC50 = 0.8 μM. | ChEMBL | ||
| MDCK | Antiviral assay | 40 hrs | Antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 40 hrs by CellTiter-Glo assay, IC50 = 6.7 μM. | ChEMBL | ||
| MDCK | Antiviral assay | 40 hrs | Antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 40 hrs by CellTiter-Glo assay, IC50 = 6.7 μM. | ChEMBL | ||
| RAW264.7 | Antiinflammatory assay | 17 hrs | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFN-gamma-stimulated nitric oxide production after 17 hrs by Griess assay, IC50 = 14.7 μM. | ChEMBL | ||
| HEK293T | Cytotoxicity assay | Cytotoxicity against HEK293T cells, IC50 = 15.2 μM. | ChEMBL | |||
| J774.1 | Cytotoxicity assay | Cytotoxicity against mouse J774.1 cells, IC50 = 31 μM. | ChEMBL | |||
| MDCK | Cytotoxicity assay | 40 hrs | Cytotoxicity against MDCK cells assessed as decrease in cell viability after 40 hrs by CellTiter-Glo assay, CC50 = 48.3 μM. | ChEMBL | ||
| MDCK | Cytotoxicity assay | 40 hrs | Cytotoxicity against MDCK cells assessed as reduction in cell viability after 40 hrs by CellTiter-Glo assay, CC50 = 48.3 μM. | ChEMBL | ||
| 3T3L1 | Function assay | 10 ng/ml | Inhibition of TNFalpha-induced NFkappaB activation (unknown origin) expressed in mouse 3T3L1 cells at 10 ng/ml by luciferase reporter gene assay | ChEMBL | ||
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
| 분자량 | 368.38 | 화학식 | C21H20O6 |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 458-37-7 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | Diferuloylmethane, Natural Yellow 3, Turmeric yellow | Smiles | COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O | ||
|
In vitro |
DMSO
: 250 mg/mL
(678.64 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| Targets/IC50/Ki |
Nrf2
(Cell-free assay) Ferroptosis
HDAC
(Cell-free assay) NF-κB
(Cell-free assay) p300
(Cell-free assay) ~25 μM
|
|---|---|
| 시험관 내(In vitro) |
Curcumin은 세포외 신호 조절 키나아제 1/2 신호 활성화를 통해 forkhead box protein O1 (FOXO1)의 발현을 유도합니다. 이 화합물은 세포 증식을 억제하며, 이는 사이클린 의존성 키나아제 억제제인 p27 및 p21의 상향 조절과 사이클린 D1의 하향 조절과 관련이 있었습니다. 또한, CCAAT/enhancer binding protein homologous protein (CHOP)의 상향 조절, JNK의 인산화 및 SERCA2ATP아제(ATPase)의 하향 조절, 사이토크롬 c의 방출, Bcl-2의 감소 및 AGS 및 HT-29 세포 모두에서 미토콘드리아 막 전위 감소로 입증된 바와 같이, 소포체(ER) 스트레스 및 미토콘드리아 기능 장애를 유도합니다. |
| 생체 내(In vivo) |
Curcumin의 만성 치료는 스트레스 받은 쥐에서 CMS 유도 행동 이상을 유의하게 역전시킵니다. 또한, 이 화합물은 mRNA 및 단백질 수준에서 사이토카인 유전자 발현을 효과적으로 억제하고 NF-κB의 활성화를 감소시킵니다. |
참조 |
|
| 방법 | 바이오마커 | 이미지 | PMID |
|---|---|---|---|
| Western blot | p-IRE1α / IREα HDAC1/ HDAC2 p-STAT3 / STAT3 |
|
29901626 |
| Immunofluorescence | β-catenin PKD1 EGFR / LC3 |
|
22523587 |
| Growth inhibition assay | Cell proliferation Cell viability |
|
22523587 |
(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)
| NCT 번호 | 모집 | 조건 | 스폰서/협력자 | 시작일 | 단계 |
|---|---|---|---|---|---|
| NCT06053411 | Not yet recruiting | Interaction |
Washington State University |
January 1 2024 | Early Phase 1 |
| NCT05947513 | Not yet recruiting | Cervical Cancer |
Addis Ababa University|Center for Innovative Drug Development and Therapeutic Trials for Africa Addis Ababa University|Akay Natural Ingredients Private Limited |
October 2023 | Phase 1|Phase 2 |
| NCT05966441 | Not yet recruiting | Chemotherapy-induced Peripheral Neuropathy |
Ain Shams University |
August 30 2023 | Phase 2 |
| NCT05774704 | Recruiting | Bioavailability|Gut Microbiome|Safety |
Texas Tech University Health Sciences Center |
August 21 2023 | Phase 1|Phase 2 |